和血明目片聯(lián)合康柏西普治療糖尿病性黃斑水腫的臨床效果觀察

打開(kāi)文本圖片集

[Abstract]Objective：To investigatethe clinical effect and safety Hexue Mingmu Tablets combined with Conbercept in the treatment diabetic macularedema （DME）.Method： A retrospective analysis was conducted on the clinical data 1O4 patients with DME who received treatment inPeople's Hospital Ruijin City from March 2022 to September 2O23，based on diferent treatment regimens，patients were divided into the observation group （52 patients，104 eyes）and the control group （52 patients，104 eyes）.Patients in both groups were treated with intravitreal injection Conbercept，and patients inthe observation group were treated withoral Hexue Mingmu Tablets on this basis.Before treatment and 1 month，3 months，6months and 12 months after treatment，the best corrected visual acuity （BCVA），central foveal thickness （CMT）and adverse reactions were evaluated in two groups. Result：At1 month，3 months，6months，and12 months after treatment，the BCVAand CMT the observation group were lower than those the control group， with statistically significant differences （ P <0.05）; there was no statistically significant difference in the incidence adverse reactions between two groups （ P. >0.05）.Conclusion： The combination Hexue Mingmu Tabletsand Conbercepthasasignificant efectinthetreatment DME，can improve the visual acuity patients，and has high safety.

[KeyWords] Hexue Mingmu TabletsConbercept Diabetic macular edemaBest corrected visual acuity 'entralmacularthickness

First-author'saddress： Otolaryngology Department，People's Hospital Ruijin City，Ruijin342500，

doi：10.3969/j.issn.1674-4985.2025.23.024

糖尿病性黃斑水腫（DME）是糖尿病眼部并發(fā)癥中最常見(jiàn)的視力損害原因之一，其發(fā)病機(jī)制復(fù)雜，主要與視網(wǎng)膜微血管損傷和血-視網(wǎng)膜屏障破壞有關(guān)[1-2]。（剩余4866字）